Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a objective signifier genome editing company, contiguous announced that it volition big a league telephone and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to supply a firm update and results for the 3rd 4th of 2022.
To entree the league call:
U.S. callers should dial 877-407-0989 and planetary callers should dial 201-389-0921 astir 5 minutes earlier the telephone begins.
Participants should inquire to beryllium connected to the Editas Medicine Earnings Conference Call.
The league telephone volition besides beryllium webcast and tin beryllium accessed from the “Investors” conception of the Editas Medicine website astatine https://www.editasmedicine.com. A replay of the telephone volition beryllium disposable astatine the aforesaid tract astir 1 hr aft the completion of the call.
About Editas Medicine
As a objective signifier genome editing company, Editas Medicine is focused connected translating the powerfulness and imaginable of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for radical surviving with superior diseases astir the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a wide people of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent property for quality medicines. For the latest accusation and technological presentations, delight sojourn www.editasmedicine.com.
Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com
English (US)